Cost of Heart Failure in Patients Receiving -Blockers and Angiotensin-Converting Enzyme Inhibitors

By Weintraub W.S.  

Clinical Drug Investigation, Vol. 24, Iss. 5, 2004-01 ,pp. : 255-264

Adis International

Access to resources Recommend Favorite

Targeting the renin–angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

By Kjeldsen Sverre E   Lyle Paulette A   Tershakovec Andrew M   Devereux Richard B   Oparil Suzanne   Dahlöf Björn   de Faire Ulf   Fyhrquist Frej   Ibsen Hans   Kristianson Krister   Lederballe-Pedersen Ole   Lindholm Lars H   Nieminen Markku S   Omvik Per   Wedel Hans  

Expert Opinion on Emerging Drugs, Vol. 10, Iss. 4, 2005-11 ,pp. : 729-745

Informa Healthcare

Access to resources Recommend Favorite

Advances in Angiotensin Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs)

By  

Mini Reviews in Medicinal Chemistry, Vol. 3, Iss. 6, 2003-09 ,pp. : 621-631

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the setting of acute myocardial infarction

By Salam Amar M  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 3, 2003-03 ,pp. : 501-507

Informa Healthcare

Access to resources Recommend Favorite

Long-Term Treatment with Angiotensin-Converting Enzyme Inhibitors, Beta-Blockers or a Combination of Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers in Low-Risk Patients after Acute Myocardial Infarction: The ABC Study

By  

Heart Drug, Vol. 1, Iss. 1, 2001-03 ,pp. : 20-25

Karger

Access to resources Recommend Favorite